1. Home
  2. COP vs VRTX Comparison

COP vs VRTX Comparison

Compare COP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConocoPhillips

COP

ConocoPhillips

HOLD

Current Price

$117.08

Market Cap

150.1B

Sector

Energy

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$444.64

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
COP
VRTX
Founded
1917
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
EDP Services
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
150.1B
115.7B
IPO Year
2005
2006

Fundamental Metrics

Financial Performance
Metric
COP
VRTX
Price
$117.08
$444.64
Analyst Decision
Buy
Buy
Analyst Count
23
29
Target Price
$123.65
$539.69
AVG Volume (30 Days)
5.6M
1.1M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
2.62%
N/A
EPS Growth
N/A
836.54
EPS
1.78
4.02
Revenue
$58,944,000,000.00
$2,488,652,000.00
Revenue This Year
$6.88
$10.79
Revenue Next Year
N/A
$10.47
P/E Ratio
$66.89
$110.02
Revenue Growth
7.67
46.20
52 Week Low
$85.59
$362.50
52 Week High
$135.87
$509.98

Technical Indicators

Market Signals
Indicator
COP
VRTX
Relative Strength Index (RSI) 45.82 56.43
Support Level $112.87 $429.02
Resistance Level $127.14 $461.66
Average True Range (ATR) 2.81 10.08
MACD 0.04 0.78
Stochastic Oscillator 34.54 83.11

Price Performance

Historical Comparison
COP
VRTX

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: